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In a recent issue of Nature, Diehn et al. (2009) demonstrate that breast cancer stem cells (CSCs) maintain
lower levels of reactive oxygen species (ROS) than their nontumorigenic counterparts. Their studies provide
a link between the management of ROS by CSCs and enhanced tumor radioresistance.In 1956, Denham Harman proposed the
‘‘free radical theory of aging,’’ hypothe-
sizing that cumulative effects of ROS on
DNA, proteins, and membranes deter-
mine the life spanof anorganism (Harman,
1956). In addition, it is now well estab-
lished that many adult tissues require
stem cells for their maintenance, and
organismal longevity is thought to be
dependent in part on the maintenance of
different tissue stem cell pools. It has
thus been suggested that effective
management of ROS in normal tissue
stem cells may contribute to their fitness,
and hence the life span of the organism.
But what might happen if this investment
in ROSmanagement by normal stem cells
were commandeered by a renegade
group of cells with the capacity to initiate
and propagate cancer? Might this
engender systemic collapse of the entire
organism?
In the hematopoietic stem cell (HSC)
compartment, protection from oxidative
stress is critical for the maintenance of
self-renewal. For example, mice deficient
in the Atm kinase or FoxO1, FoxO3, and
FoxO4 transcription factors exhibit
elevated ROS levels in the HSC compart-
ment that result in a rapid extinction of
HSCs. Furthermore, the demise of these
mutant HSCs can be reverted by in vivo
antioxidant therapy (Ito et al., 2004; Miya-
moto et al., 2007; Tothova et al., 2007),
indicating a causal link between ROS
and HSC longevity.
However, protection of HSC from the
accumulation of ROS is abandoned with
the transition of HSC to myeloid progeni-
tors. This developmental transition is
associated with an 100-fold increase in
ROS, and enables the mature progeny of
non-self-renewing myeloid progenitors196 Cell Stem Cell 4, March 6, 2009 ª2009 Eto engage their role as professional gener-
ators of ROS with bactericidal intent
(Tothova et al., 2007).
Diehn et al. now extend this paradigm
into the realm of epithelial tissue stem
cells. In their elegant report, the authors
demonstrate developmental regulation of
ROS levels in the context of mammary
epithelial stem cells and their progeny.
They convincingly demonstrate that
human and mouse breast CSCs, similar
to their normal tissue counterparts, main-
tain low levels of ROS that afford radiopro-
tection, providing a possible explanation
for tumor recurrence with therapy (Diehn
et al., 2009).
Diehn et al. made the initial observation
that a population of murine mammary
repopulating unit (MRU)-enriched cells
harbors lower levels of ROS and mito-
chondrial superoxide than do murine
mammary progenitor cells, further
emphasizing the importance of low levels
of physiologic oxidative stress among
different tissue stem cell compartments.
They extended these findings to breast
CSCs and addressed whether CSCs also
have mechanisms that protect them from
detrimental effects of oxidative stress.
There are several reasons why this issue
may be of particular relevance to CSCs.
First, the cell of origin of CSCs may
influence the levels of ROS and the tran-
scriptional programs available for ROS
management. For example, if a CSC pop-
ulation arose from committed progenitors
in either the breast epithelial compartment
or the myeloid progenitor compartment,
endogenous ROS would be predicted to
be higher than if CSCs arose from a stem
cell. Second, CSCs demonstrate activa-
tion of signaling pathways that result in
increased production of ROS and extinc-lsevier Inc.tion of normal stem cells, such as the
PI3K/AKT axis that results in inactivation
of FoxO. Thus, CSCs may have mecha-
nisms for protection from ROS, either
through activation or reactivation of phys-
iologic mechanisms that maintain low
levels of ROS, or development of resis-
tance to predicted detrimental effects of
high ROS on self-renewal of CSCs. Diehn
et al. (2009) provide evidence that the
former is the case in the context of
mammary CSCs.
First, gene set enrichment analysis
(GSEA) using microarray expression data
sets derived from human breast CSC-en-
riched populations (ESA+CD44+CD24/
low Lin) or nontumorigenic breast
cancer cells (‘‘NTCs,’’ CD24+Lin) shows
that genes involved in ROS metabolism,
including glutathione peroxidase 1 and
4, superoxide dismutase 2, and catalase,
are enriched in CSCs. Furthermore,
enrichment of antioxidant gene expres-
sion correlates with lower levels of ROS
in human breast CSC-enriched popula-
tions relative to NTCs, although ROS
expression levels were heterogeneous
within both populations of cells.
In addition, a CSC-enriched population
derived from an MMTV-Wnt1 murine
model of spontaneous breast cancer
exhibits lower overall levels of ROS than
NTCs. However, transplantation of both
low-ROS and high-ROS CSC-enriched
populations gives rise to tumors, and
a higher tumor-forming efficiency was
noted in the high-ROS group. These data
are somewhat perplexing and argue that
in this setting, levels of ROS do not corre-
late with transplantability of the CSC
population. This finding also stands in
contrast with the hematopoietic system,
at least in the context of nonmalignant
Cell Stem Cell
PreviewsHSCs (Ito et al., 2006; Tothova
et al., 2007).
Although deleterious
effects of ROS include induc-
tion of DNA damage and
genetic instability, certain
ROS also regulate a variety
of cellular functions
(reviewed in Veal et al.,
2007). To assess the physio-
logical relevance of low levels
of ROS in breast CSCs, Diehn
et al. (2009) examined the
propensity of breast CSC-en-
riched populations to develop
DNA damage after ionizing
radiation (IR). They observed
that CSC-enriched popula-
tions accumulate fewer DNA
single- and double-strand
breaks after in vitro and
in vivo irradiation. In addition,
the decrease in DNA damage
correlates with increased
persistence of the CSC-
enriched population, consis-
tent with the model that ROS
modulates radioresistance of
the CSC population. Further-
more, radioprotection in the
CSC-enriched population is
linked to expression of genes
involved in glutathione
synthesis, including gluta-
mate cysteine ligase (Gclm), glutathione
synthetase (Gss), and FoxO1, but not
FoxO4,Hif1a, orEpas1. In addition, deple-
tion of GSH in CSC via treatment with bu-
thionine sulphoximine (BSO) results in
decreased colony-forming ability and ra-
diosensitization (Figure 1). In contrast,
pretreatment with the antioxidant tempol
protects NTCs from radiation-induced
death to the same extent as that of the
CSC-enriched population.
Additional key mediators of ROS induc-
tion and genomic stability identified in
other tissue stem cell contexts also
warrant further investigation, including
ATM, FoxO3, p53, p66Shc, NRF2-ARE,
and p38MAPK, among others. In addition,
it will be of interest to determine the contri-
bution ofmicroenvironmental regulation of
ROS and genomic instability in this
context. Forexample, expressionofmatrix
metalloproteinase-3 (MMP3) in breast
tumors is implicated in increased produc-
tion of ROS with resultant DNA damage
and genomic instability (Radisky et al.,
2005). Microenvironmental contribution
to these processes could potentially
explain the heterogeneity in ROS levels
that was observed in the CSC-enriched
population in the aforementioned experi-
ments. Finally, it remains to be determined
whether differential expression of ROS in
breastCSCs versusNTCsmayserve addi-
tional regulatory functions. For example,
ROS has been implicated in activation of
signaling pathways in response to cyto-
kines, such as differentiation or induction
of apoptosis.
Taken together, these intriguing find-
ings suggest that the self-renewal poten-
tial of CSCs in different tissues may be
exquisitely sensitive to levels of reactive
oxygen, and that the redox state may
be intimately linked to resistance to IR.
If so, this liability might represent a CSC
‘‘Achilles’ heel’’ for future therapeutic
exploitation. Indeed, there is
evidence suggesting that
treatment of human AML
stem and progenitor cells
with parthenolide, a naturally
occurring molecule that
induces ROS, preferentially
targets AML cells and
induces robust apoptosis
(Guzman et al., 2005). It
remains to be seen whether
CSCs in other tissue
compartments maintain low
levels of ROS or whether
they utilize other protective
mechanisms to ‘‘bail out’’
the population from meta-
bolic debts accumulated
over time. A more thorough
mechanistic understanding
of these observations may
inform the pursuit of
improved therapeutic target-
ing of this critical tumor cell
population.
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Figure 1. Breast CSCs Exhibit Low Levels of ROS and Increased
Radiation Resistance
Treatment of breast tumors with ionizing radiation (IR) results in selective
survival of breast cancer stem cells (CSCs; left), but not their nontumorigenic
counterparts (top). Glutathione (GSH) synthesis, regulated by Gclm (glutamate
cysteine ligase) and Gss (glutathione synthetase), and transcription factor
FoxO1, is reduced following treatment with buthionine sulphoximine (BSO)
and results in increased levels of ROS, radiosensitization of breast CSCs,
and abolishment of selective survival of breast CSCs in the presence of IR
(right).Cell Stem Cell 4, March 6, 2009 ª2009 Elsevier Inc. 197
